WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) Stock Price

Wakamoto Pharmaceutical operates four business segments.

1. **Pharmaceutical Business**: Wakamoto Pharmaceutical manufactures and sells branded pharmaceuticals, generic drugs, medical devices, and health foods, with a focus on ophthalmology. This enables the company to meet the needs of healthcare providers.

2. **Healthcare Business**: In addition to its flagship product "Koryoku Wakamoto," the company manufactures and sells medicinal toothpaste products under the "Avanbees" series and femcare products such as "Femiflora." These products support daily health maintenance.

3. **Global Business**: The company exports products such as "Koryoku Wakamoto" and pharmaceutical raw materials, primarily to Asia and Europe. It also pursues new licensing-in and licensing-out activities. Domestically, the company engages in contract manufacturing and manufactures and sells diagnostic reagents and raw materials.

4. **Real Estate Rental Business**: The company primarily operates rental operations related to Coredo Muromachi. This business serves as a stable revenue source supporting the company's operational foundation.

These business segments align with the segment information presented in Wakamoto Pharmaceutical's financial statements.

Wakamoto Pharmaceutical has formulated its medium-term management plan "Wakamoto 100—Succession and Challenge" for fiscal years 2024-2028, aiming for sustainable growth. This plan leverages the company's long-standing business experience and management resources while pursuing new initiatives. The company places particular emphasis on securing capital returns exceeding its cost of capital, targeting an ROE of 8.0% or higher by fiscal year 2028.

The company's growth strategy is based on four core pillars: pharmaceutical business, healthcare business, global business, and research and development. In the pharmaceutical business, the company is advancing as a specialty pharmaceutical company in the ophthalmology field, developing new pharmaceutical products and medical devices. It is particularly focused on developing intraocular lenses and perioperative medications to enhance synergies.

In the healthcare business, the company is developing new products centered on the "Riyokuwakamoto" brand, including femcare products. It is improving production capacity and establishing stable supply systems to meet inbound demand and support overseas expansion. In the global business, the company is strengthening brand presence through sales in Asian countries and cross-border e-commerce.

In research and development, the company is advancing product development targeting the ophthalmology field while promoting the development of new health-related products leveraging the Wakamoto brand. In the production division, the company is working to establish efficient and stable manufacturing systems and strengthen quality control.

Through these strategies, Wakamoto Pharmaceutical aims to enhance corporate value and realize sustainable management. Further details are available in the company's medium-term management plan.